版本:
中国

BRIEF-Flexion Therapeutics says Zilretta demonstrated meaningful pain relief, functional improvement

April 28 Flexion Therapeutics Inc

* Flexion Therapeutics - in analysis of pooled phase 2/3 data, Zilretta (FX006) demonstrated clinically meaningful pain relief, unctional improvement

* Flexion - separate phase 2 study shows prolonged synovial localization, diminished systemic exposure of corticosteroid with zilretta versus. steroid injections

* Flexion Therapeutics Inc - authors examined improvements in pain and function using pooled data from three phase 2 and 3 randomized trials

* Flexion Therapeutics - pooled data from 3 phase 2, 3 randomized trials individually demonstrated statistically significant reductions in weekly mean scores of ADP Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐